Summary of the Text:
This text details the HERA Project, a research initiative focused on early detection of a rare and aggressive type of breast cancer that occurs during or shortly after pregnancy and breastfeeding (pregnancy-associated and postpartum breast cancer). Here’s a breakdown of the key points:
The Project: HERA aims to create the world’s largest breast milk biobank to analyse samples for biomarkers of this cancer. Breast milk is seen as a “biological window” offering a non-invasive way to study the mammary tissue.
The Discovery: The idea stemmed from clinical observations in 2013 linking young mothers to postpartum breast cancer. Research (EMbarCAm Project) showed this cancer is biologically distinct and often more aggressive.
Current Status: Four mothers have been diagnosed through the project – three from Córdoba and one from Seville – and are receiving standard treatment.
Breastfeeding & Cancer: The research does not suggest breastfeeding increases cancer risk.In fact, it’s consistently shown to be beneficial for both mother and baby, aiding recovery and reducing cancer risk.* Breast Milk as a Biomarker: Breast milk contains cells and genetic material from the mammary glands, making it a potential source for early cancer detection.
In essence, the HERA Project is a proactive effort to improve outcomes for women affected by this specific type of breast cancer by leveraging the unique properties of breast milk for early diagnosis.
